ASCO GU 2025

Milestones of ADT and ARPI treatment in the metastastic…

What's the role of Enzalutamide in radioligand therapy?

Darolutamide + ADT reduces risk of progression or death…

Mevrometostat + Enza: New option for mCRPC

ARPI for which patients?

OS in the TALAPRO-2 trial

Hypo-gonadism bad for survival?

Who benefits most from ARPIs?

Final OS data for TALA + Enza

Testosterone Recovery after ADT and OS

ENZA-p showed OS benefit and improvement in QoL…

Phase 2 Mevrometostat

Durvalumab in UTUC

Final OS analyses

Fish-oil supplement for pts on active surveillance

Darolutamide + ADT and Doetaxel improves survivas in…

Improved Survival with Enzalutamide + Lutetium

Testosterone Recovery

Local radiotherapy of oligoprogressive mCRPC

Radical Prostatectomy VS RT in HRPC

MDT in OMPC

Radiation vs surgery in high risk prostate cancer

Oligometastatik PCa da MDT

Yuksek risk PCa da RP vs RT

Hangi hastalarda ADT+ARPI

Testosteron Geri Gelisi ve Sagkalim

UTUC de Neoadj. Durvalumab+Kemo

Triplet combination in RCC - there's no free lunch with…

New data but no new conclusion

Exciting new substances - but don't over-estimate phase…

New agents / new mode of actions

KIM-1 in CheckMate 214

New data nccRCC

Proactive coaching of patients with TKI +/- IO therapy

AVION trial at mRCC

Casdatifan in refracting RCC

Prognostic and predictive biomarkers in mRCC: Looking…

Firstline Update Kidney Cancer

KIM-1 in mRCC

Biomarcadores prognósticos y predictivos en el CCRm: en…

ADC + ICI - The future for MIBC?

Exploratory analyses of pCR in NIAGARA: who benefits…

New data, but no new insights for adjuvant treatment of…

Reassuring data on established ADCs and new insights in…

The role of ctDNA in bladder cancer

Durvalumab + Platinum-based chemotherapy shows…

Sacituzumab Tirumotecan shows promising antitumor…

New drugs in mUC: The active field of ADCs

Neoadjuvant treatment for UTUC

ASCO GU 25 - Summary: Urothelial Cancer

Phase 2 Mevrometastat

EV-Pembro continues to be the standard for mTCC

Promising combination for perioperative setting

Adjuvant Nivo - independent from previous therapy

A possible new standard for mUC

New FGFR3 inhibitor

Bladder-sparing approaches - are we there yet?

Updates neo/adjuvant therapy in MIBC

Nivo adjuvant in MIBC - a new standard

Preliminary results of neoadjuvant chemoimmunotherapy…

Nuevos fármacos en mUC: El campo activo de las ADCs

ASCO GU 25 - Περίληψη: Ουροθηλιακός καρκίνος

Testicular cancer: Reinventing the wheel

Metastatik seminomda Primer RPLND